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Sirs,
The oldest of three sisters, two of whom are monozygous
twins, presenting all with atypical hemolytic uremic
syndrome (aHUS) associated with a CFH mutation, was
referred at the age of 3 years to the Emma Children’s
Hospital/Academic Medical Centre of Amsterdam (Fig. 1)
[1, 2]. She never recovered renal function and commenced
peritoneal dialysis. Bilateral nephrectomy was performed
1 year later because of hypertension. She lost two
transplants by recurrence, one immediately posttransplan-
tation and the other one 2 months posttransplant despite
preventive plasma exchanges (PEs) contemporary to
frequency reduction of PE. From the age of 15 years,
she began to experience transient sensory and motor
symptoms on both sides of her body associated with low
blood pressure (BP) during hemodialysis. Magnetic
resonance angiogram (MRA) showed severe stenoses of
both middle and both anterior cerebral arteries (Fig. 2a)
(partial report in [3]). She did not present any additional risk
factors for developing arteriosclerosis (such as long-duration
hypertension, diabetes, uncontrolled hyperparathyroidism).
No arterial calcification and no left ventricular hypertrophy
were shown.
At the age of 17 years, the patient was transplanted for
the third time under pre- and postoperative prophylactic
PEs [1, 2]. Postoperatively, she developed infarcts in the
right frontal and frontoparietal regions (Fig. 2b). She
recovered almost completely. Ten months after transplan-
tation, the child developed bronchospasm and hypotension
during PE. For this reason, she was switched to eculizu-
mab [2]. Under this treatment, she presented no HUS
recurrence, and renal function remained stable (plasma
creatinine 120 μmol/L) 16 months after PE discontinua-
tion. The first of her twin sisters (twin 1) developed aHUS
at the age of 5.3 years. She required chronic dialysis
despite initial daily PE for 10 days and three intermittent
courses of fresh frozen plasma (FFP) infusions. Two years
later, she received a cadaver renal transplant under PE
prophylaxis. At 7.5 years follow-up, the graft function is
satisfactory (serum creatinine 137 μmol). The second twin
(twin 2) presented aHUS at the age of 5.8 years (Fig. 1)
[1]. She was treated immediately with daily PE and,
following remission, with one PE every 2 weeks to this
time. At 9.5 years after HUS onset, native renal function
(serum creatinine 49 μmol/L) was normal. MRA showed
normal cerebral vasculature in both twins at age 14 years
(Fig. 2c). Contrary to their older sister with cerebral artery
stenoses who was treated by prophylactic PE for 2 months
only, the twin sisters received prophylactic PE without
interruption for, respectively, 7.5 (twin 1) and 9 (twin 2)
years.
Although brain ischemia sometimes resulting in cerebral
infarct is observed in aHUS, stenosis of large vessels has
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Fig. 1 Clinical course in patient and her twin sisters
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c
Fig. 2 Three-Tesla magnetic
resonance images (MRIs) of
patient 2 (a, b) and her sister (c).
Coronal 3D time-of flight (TOF)
MRA maximum intensity pro-
jection (MIP) (a) image of pa-
tient at the age of 15 years
demonstrates (near) occlusion of
the M1 segment of the right
middle cerebral artery (thick
arrow) and the A1 segment of
the right anterior cerebral artery
(long arrow), and severe steno-
sis of the M1 segment of the left
middle cerebral artery (thick
arrow) and the A1 segment of
the left anterior cerebral artery
(long arrow). Axial fluid-
attenuated inversion recovery
(FLAIR) MRI (b) of the patient
at the age of 17 years shows
infarct in right middle and ante-
rior cerebral arteries. Coronal
3D TOF MRA MIP image (c) of
the sister of patient 2 at the age
of 14 years shows normal ap-
pearance of intracranial arteries.
Basilar artery and side branches
were manually removed from
the 3D data sets in a and c to
better demonstrate the anterior
cerebral arteries
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been reported in aHUS only once—in a child presenting
with a Lys350Asp gain of function CFB mutation [4]. Of
note, this patient, as ours, was dialyzed for long periods
from the age of 4 months. At the age of 10 years, she
started having episodes of bilateral hemiparesis during
hemodialysis in relation with multiple stenoses of cerebral
arteries. Stenoses of large arteries have never been reported
as a complication of renal replacement therapy (RRT) in
children [5]. Chronic continuous complement dysregulation
might contribute to vascular lesions. Indeed complement
activation occurs both in human and experimental athero-
sclerosis, and the deposition of C5b-9 correlates with
disease state [6].
Our patient and the patient reported recently by Loirat et
al. [4] suggest that aHUS with complement dysregulation, a
disease of microvascularization, may also involve large
arteries, especially when patients have to face long periods
of dialysis when plasma therapy is not used. The latter
reports also raise the question of preventing vascular
lesions by avoiding complement system disorders. This
emphasizes the importance of including patients at an early
stage in specific programs of kidney transplantation using
preventive plasma therapy or combined liver transplanta-
tion. Inhibition of the complement system by anti-C5
antibody that is actually under investigation might be
valuable for this purpose in the future [2].
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